Pharmaceuticals, Biotechnology and Life Sciences
Incubator program biotope launches today to support biotech startup teams looking to impact people’s lives through innovation.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has reported €73 million net loss in its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.
The US Food and Drug Administration (FDA) has approved Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer
Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.
Kayentis, a global provider of eCOA and Decentralized Clinical Trial solutions, has announces the launch of a fully integrated patient-centric…
ONK Therapeutics has appointed Allan Reine as independent Non-Executive Director to its Board.
Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany.
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.